ALFA Finder| Revenue growth | 17.0% YoY for FY26. |
|---|---|
| Margins | Adjusted EBITDA margin improved 400bps in Q4 YoY to 27.1%. |
| Demand visibility | Strong momentum in specialty and chronic therapies. |
| Management confidence | High on chronic segment growth and BSV integration. |
Growth
FY26 revenue grew 17% YoY to INR 14,278cr; Domestic revenue up 14.4% for the full year.
Outlook
FY27 EBITDA margin guidance of 25.5-26.5%; capex of 6-7% of revenue for biotech facility.
Risks
Geopolitical headwinds impacting exports; raw material and packaging cost volatility due to Middle East issues.
Earnings Call filed with NSE, NSE: MANKIND. Summary written with AI assistance from the document.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,645.60
- Market cap
- ₹1,09,275 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 48.7×Sector 43.8×
- Promoter holding
- 72.62%-0.01% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Other Announcement
Mankind Pharma Limited received an ESG rating of 64.8 from SES ESG Research. This rating was independently assigned for FY26 based on publicly available information.
Mankind Pharma Credit Rating
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.
Mankind Pharma Earnings Call Transcript: Key Takeaways
Mankind Pharma delivered robust Q2 growth driven by chronic therapies and B-Spec specialty expansion. Strong operating leverage and margin expansion offset muted consumer health performance.
- Call
- Guides 20% growth
Mankind Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹4,338 Cr (+17.3% YoY), EBITDA ₹1,175 Cr (27.1% margin), PAT ₹716 Cr (+37.7%). Domestic ex-CH +15.9%, exports +32.7%, CH +1.2%.
Mankind Pharma Results Update
Mankind Pharma reported Q2 FY27 revenue of ₹4,338 Cr, up 17% YoY, and PAT of ₹716 Cr, up 38%. EBITDA margin improved 210 bps to 27.1%.
Mankind Pharma Acquisition
Mankind Pharma's board approved amalgamation of two wholly owned subsidiaries into the parent and a step-down subsidiary merger into MCPPL. Schemes require NCLT and shareholder approvals.